Please login to the form below

Not currently logged in
Email:
Password:

peglispro

This page shows the latest peglispro news and features for those working in and with pharma, biotech and healthcare.

Lilly's Lantus 'follow-on' approved in the US

Lilly's Lantus 'follow-on' approved in the US

Approval is a boost to Lilly, which decided earlier this month to abandon development of another Lantus rival - insulin peglispro - after concluding data on a potential toxicity issue made the project

Latest news

  • Lilly says insulin peglispro too risky to pursue Lilly says insulin peglispro too risky to pursue

    Discontinues development of medicine once tipped as a diabetes blockbuster.  . Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for type 1 and ... Analysts have been divided on the

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    However, there was some good news for Novo Nordisk when it emerged Eli Lilly had delayed filings for its long-acting insulin peglispro candidate after a safety signal was seen in

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The company also released the results of five phase III studies of its long-acting insulin peglispro, which had a serious setback earlier this year when liver fat changes seen in ... However, some of the IMAGINE trials showed an increase in the liver

  • Sanofi wins European approval for Lantus follow-up Toujeo Sanofi wins European approval for Lantus follow-up Toujeo

    However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for Lilly's insulin peglispro were delayed recently due to safety concerns.

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    Until recently, additional competition was also looming in the form of Lilly's long-acting insulin peglispro, although that project has now been significantly delayed after fatty liver changes were seen

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics